State Board of Administration of Florida Retirement System Sells 3,280 Shares of DaVita Inc. (NYSE:DVA)

State Board of Administration of Florida Retirement System lessened its stake in DaVita Inc. (NYSE:DVA) by 4.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 73,574 shares of the company’s stock after selling 3,280 shares during the period. State Board of Administration of Florida Retirement System owned about 0.08% of DaVita worth $5,968,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of DVA. Norges Bank bought a new position in DaVita in the fourth quarter worth $116,373,000. Amundi grew its stake in shares of DaVita by 226.3% in the 4th quarter. Amundi now owns 659,372 shares of the company’s stock valued at $52,592,000 after purchasing an additional 457,285 shares during the period. Morgan Stanley raised its holdings in shares of DaVita by 37.9% in the 4th quarter. Morgan Stanley now owns 1,232,647 shares of the company’s stock worth $92,042,000 after buying an additional 339,051 shares in the last quarter. Point72 Asset Management L.P. boosted its stake in DaVita by 912.4% in the 4th quarter. Point72 Asset Management L.P. now owns 338,139 shares of the company’s stock valued at $25,249,000 after buying an additional 304,739 shares in the last quarter. Finally, Glenview Capital Management LLC bought a new stake in DaVita in the first quarter valued at $22,401,000. 84.69% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Kathleen Alyce Waters sold 9,794 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $101.81, for a total value of $997,127.14. Following the transaction, the insider now owns 81,297 shares of the company’s stock, valued at approximately $8,276,847.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.40% of the company’s stock.

DaVita Stock Up 1.5 %

Shares of NYSE:DVA opened at $99.78 on Tuesday. The firm has a market cap of $9.11 billion, a P/E ratio of 19.84, a P/E/G ratio of 1.08 and a beta of 0.94. The company has a quick ratio of 1.20, a current ratio of 1.25 and a debt-to-equity ratio of 7.13. The company’s 50-day moving average price is $102.60 and its two-hundred day moving average price is $94.36. DaVita Inc. has a 12 month low of $65.28 and a 12 month high of $116.97.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $2.08 EPS for the quarter, beating analysts’ consensus estimates of $1.66 by $0.42. The firm had revenue of $3 billion for the quarter, compared to analyst estimates of $2.95 billion. DaVita had a return on equity of 60.67% and a net margin of 3.98%. The business’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same period last year, the company earned $2.30 EPS. As a group, research analysts forecast that DaVita Inc. will post 7.22 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

DVA has been the topic of several recent analyst reports. UBS Group upgraded shares of DaVita from a “neutral” rating to a “buy” rating and boosted their target price for the company from $100.00 to $142.00 in a research note on Monday, August 7th. Truist Financial boosted their target price on shares of DaVita from $100.00 to $115.00 and gave the company a “hold” rating in a research note on Thursday, July 13th. Finally, StockNews.com downgraded shares of DaVita from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, September 13th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $105.29.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.